GlassScriptPhysician profile
Jaime Burkle
NPI 1326042052
$628,053.61
in general payments reported to CMS, 2019-2025
39 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137K · 2020: $102K · 2021: $145K · 2022: $58K · 2023: $72K · 2024: $67K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Consulting Fee: $27K · Travel and Lodging: $23K · Food and Beverage: $5,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,518.75 |
| Consulting Fee | $26,690.00 |
| Travel and Lodging | $22,766.09 |
| Food and Beverage | $5,873.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $203,653.99 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $182,495.01 | 2020-2025 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75,076.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $47,725.96 | 2019-2025 | Jardiance |
| Pfizer INC. | $42,816.81 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $16,878.05 | 2019-2025 | Leqvio |
| Regeneron Pharmaceuticals, INC. | $16,693.55 | 2022-2024 | |
| Akcea Therapeutics, INC. | $16,619.66 | 2019 | |
| Pharmacosmos Therapeutics INC. | $12,557.43 | 2021-2024 | Monoferric |
| Daiichi Sankyo INC. | $6,814.32 | 2019-2022 | |
| Medtronic Vascular, INC. | $1,755.68 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,612.13 | 2019-2021 | |
| Amarin Pharma, INC. | $446.36 | 2019-2021 | |
| Boston Scientific Corporation | $440.65 | 2020-2025 | Watchman Flx, Watchman Access System, Latitude Communicator Power Supply |
| Astrazeneca Pharmaceuticals LP | $423.57 | 2019-2023 | Farxiga |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $291.75 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $248.22 | 2019-2023 | Evkeeza, Praluent |
| E.R. Squibb & Sons, L.L.C. | $242.59 | 2019-2023 | Eliquis |
| Medtronic, INC. | $190.19 | 2021-2024 | Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $169.70 | 2021-2022 | |
| Eisai INC. | $148.49 | 2024 | |
| Bracco Diagnostics INC. | $93.85 | 2023-2024 | |
| Abbott Laboratories | $80.99 | 2020-2022 | |
| Chiesi USA, INC. | $79.69 | 2025 | Juxtapid, Myalept |
| Heartflow, INC. | $78.51 | 2023-2024 | Ffrct |
| Philips North America LLC | $65.55 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Sanofi-Aventis U.S. LLC | $64.31 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $63.25 | 2020-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $42.23 | 2021-2023 | Arcalyst |
| Astellas Pharma US INC | $30.43 | 2020-2021 | |
| Lantheus Medical Imaging, INC. | $28.70 | 2021 | |
| American Regent | $22.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.63 | 2021 | |
| Exact Sciences Corporation | $19.52 | 2025 | The Cologuard Plus Collection Kit |
| Amryt Pharma Holdings LTD | $19.09 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.86 | 2020 | |
| Novo Nordisk INC | $13.17 | 2024 | Ozempic, Rybelsus |
| Medicure Pharma INC. | $12.58 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Burkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.